Shared Resources Laboratories (SRL) are fundamental cornerstones of the 2003 NIH Roadmap. Often referred to as core laboratories, SRLs are the most cost-effective approach to provide a broader range of scientific expertise from skilled technology scientists and advanced instrumentation than would be feasible or economically-viable for individual laboratories. Best practices for a Flow Cytometry SRL include: 1) stable and consistent financial support, 2) a highly qualified scientific director (head), 3) policies conducive to recruitment and retention of highly skilled technical staff, 4) user training and staff continuing education, 5) a quality control program for the instruments, 6) support for research and development, 6) overview of satellite facilities), and 7) at a minimum, a 5-year plan for future technology expansion and operation. The NIA Flow Cytometry Unit is organized and managed in a manner consistent with the policies and staffing levels of flow cytometry cores at extramural academic institutions and at NIH. A survey (updated March 2011) of these sites (9 NIH, 133 academic, total 142) indicates that in 91.4% of the cores, sorting is performed only by core personnel. The reason for this is twofold: 1) it is the most efficient way to provide reliable services to the IRP (i.e. minimizing the possibility of instrument abuse by users and thus removing the cascading effect that this has on the ability to complete the next scheduled users sort, especially when the core is heavily booked). 2) neither the MoFlo nor iCyt are turnkey black box, menu-driven instruments (nor is the Aria II in the case of the ability to troubleshoot). Sort usage has expanded in parallel with instrument capacity. For FY11, the core ran at 102% of capacity. Relevance to the NIA IRP Program In addition to the level of core utilization by investigators, measurement of the effectiveness and value of the core to IRP productivity is evident from the 135 publications (including in press and submitted) generated by NIA investigators using flow cytometry/sorting as an integral part of their research since the cores inception in 1999. Seventy-eight (78) of these publications covers the time span from mid 2005 to the present. A partial list of these includes J Immunology (10), BMC Immunology (2), J Exp Med (1), Cellular Immunology (2), Immunity (1), Nature Immunology (1), Blood (2), Cancer Res (1), PNAS USA (3), Endocrinology (1), PLOSone (3), DNA Repair (3), Mol Cell Biol (3), EMBO J (1), and Nature (1), other journals (43). 98.5% of research papers using core services are from NIA IRP investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICAG000618-05
Application #
8554063
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2012
Total Cost
$916,628
Indirect Cost
Name
National Institute on Aging
Department
Type
DUNS #
City
State
Country
Zip Code
Illuzzi, Jennifer L; McNeill, Daniel R; Bastian, Paul et al. (2017) Tumor-associated APE1 variant exhibits reduced complementation efficiency but does not promote cancer cell phenotypes. Environ Mol Mutagen 58:84-98
Wnorowski, Artur; Such, Justyna; Paul, Rajib K et al. (2017) Concurrent activation of ?2-adrenergic receptor and blockage of GPR55 disrupts pro-oncogenic signaling in glioma cells. Cell Signal 36:176-188
Lee-Chang, Catalina; Bodogai, Monica; Moritoh, Kanako et al. (2016) Aging Converts Innate B1a Cells into Potent CD8+ T Cell Inducers. J Immunol 196:3385-97
Bodogai, Monica; Moritoh, Kanako; Lee-Chang, Catalina et al. (2015) Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. Cancer Res 75:3456-65
Cheng, Nai-Lin; Chen, Xiaochun; Kim, Jiewan et al. (2015) MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age. Aging Cell 14:200-8
Boheler, Kenneth R; Bhattacharya, Subarna; Kropp, Erin M et al. (2014) A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets. Stem Cell Reports 3:185-203
Bodogai, Monica; Lee Chang, Catalina; Wejksza, Katarzyna et al. (2013) Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res 73:2127-38
Valle, Blanca L; D'Souza, Theresa; Becker, Kevin G et al. (2013) Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One 8:e61836
Wersto, Robert P; Koss, Leopold G (2012) Intratumor heterogeneity and branched evolution. N Engl J Med 366:2132; author reply 2133
Gundry, Rebekah L; Riordon, Daniel R; Tarasova, Yelena et al. (2012) A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells. Mol Cell Proteomics 11:303-16

Showing the most recent 10 out of 23 publications